

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT3663722

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
AMGEN FREMONT, INC.	04/25/2007
RECEIVING PARTY DATA	
Name:	ASTRAZENECA AB
Street Address:	SE-151 85
City:	SODERTALJE
State/Country:	SWEDEN
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	14875812
CORRESPONDENCE DATA	
Fax Number:	(301)398-9306
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Email:	ipdocketing@medimmune.com
Correspondent Name:	MEDIMMUNE, LLC
Address Line 1:	ONE MEDIMMUNE WAY
Address Line 4:	GAITHERSBURG, MARYLAND 20878
ATTORNEY DOCKET NUMBER:	IGF-100US4
NAME OF SUBMITTER:	KIM NOROOZI
SIGNATURE:	/Kim Noroozi/
DATE SIGNED:	12/17/2015
Total Attachments: 5	
source=2007-04-25 executed Amgen Fremont#page1.tif	
source=2007-04-25 executed Amgen Fremont#page2.tif	
source=2007-04-25 executed Amgen Fremont#page3.tif	
source=2007-04-25 executed Amgen Fremont#page4.tif	
source=2007-04-25 executed Amgen Fremont#page5.tif	

PATENT
Page 1

ASSIGNMENT

WHEREAS, Amgen Fremont Inc., a Delaware corporation having offices at 6701 Kaiser Drive, Fremont, CA 94555 (hereinafter "ASSIGNOR"), represents and warrants that it has an ownership interest to certain new and useful improvements for which ASSIGNOR has filed the following United States applications for Letters Patents in the United States (hereinafter "the Patent Applications"):

TITLE	APPLICATION NO.	FILING DATE
ANTIBODIES DIRECTED TO MONOCYTE CHEMO-ATTRACTANT PROTEIN- 1 (MCP-1) AND USES THEREOF	10/644,277	August 19, 2003
ANTIBODIES DIRECTED TO ANGIOPOIETIN-2 AND USES THEREOF	11/311,939	December 19, 2005
ANTIBODIES DIRECTED TO CD20 AND USES THEREOF	11/440,728	May 25, 2006
BINDING PROTEINS SPECIFIC FOR INSULIN-LIKE GROWTH FACTORS AND USES THEREOF	11/608,705	December 8, 2006
ANTIBODIES DIRECTED TO α VB6 AND USES THEREOF	60/835,559	August 3, 2006
ANTIBODIES DIRECTED TO PDGFR-ALPHA AND USES THEREOF	60/835,547	August 3, 2006

WHEREAS, AstraZeneca AB, a Swedish corporation having offices at Södertälje, SE - 151 85, Sweden (hereinafter "ASSIGNEE") desires to purchase the ASSIGNOR'S entire right, title, and interest in and to the inventions disclosed in the Patent Applications;

NOW, THEREFORE, for good and valuable consideration, the receipt of which is hereby acknowledged, ASSIGNOR hereby further acknowledges that it has sold, assigned, and transferred, and by these presents does hereby sell, assign, and transfer, unto ASSIGNEE, its successors, legal representatives, and assigns, its entire right, title, and interest throughout the world in, to, and under the said improvements, and the said Patent Applications and all Patents that may be granted thereon, and all provisional applications relating thereto, and all divisions, continuations, reissues, reexaminations, renewals, and extensions thereof, and all rights of priority under International Conventions and applications for Letters Patent that may hereafter be filed for said improvements or for the said Patent Applications in any country or countries foreign to the United States, including but not limited to those in Attachment A; and ASSIGNOR hereby authorizes and requests the Commissioner of Patents of the United States, and any Official of any country foreign to the United States, whose duty it is to issue patents on applications as aforesaid, to issue all Letters Patent for said improvements and all Letters Patents resulting from the Patent Applications to ASSIGNEE, its successors, legal representatives, and assigns, in accordance with the terms of this Agreement.

PATENT
REEL: 019654 FRAME: 0973PATENT
REEL: 037319 FRAME: 0403

PATENT
Page 2

ASSIGNOR does hereby sell, assign, transfer, and convey to ASSIGNEE, its successors, legal representatives, and assigns all claims for damages and all remedies arising out of any violation of the rights assigned hereby that may have accrued prior to the date of assignment to ASSIGNEE, or may accrue hereafter, including, but not limited to, the right to sue for, collect, and retain damages for past infringements of the said Patents before or after issuance;

IN TESTIMONY WHEREOF, I hereunto set my hand and seal this 25th day of

April, 2007

Angen Fremont Inc.

By: Stuart L. Watt

Name Printed: Stuart L. Watt

Title: Vice President, Law

Date: _____



STATE OF California }
COUNTY OF Ventura } ss.


On April 25, 2007 before me, Karen E. Podgorny, notary public, personally appeared * personally known to me (or proved to me on the basis of satisfactory evidence) to be the person(s) whose name(s) is/are subscribed to the within instrument, and acknowledged to me that they executed the same in their authorized capacity(ies), and that by their signature(s) on the instrument the person(s), or the entity upon behalf of which the person(s) acted, executed the instrument.

WITNESS my hand and official seal.

[SEAL]

Karen E. Podgorny
Notary Signature

34526881cey
022107



PATENT
REEL: 019654 FRAME: 0974

PATENT
REEL: 037319 FRAME: 0404

PATENT
Page 3

ATTACHMENT A

Title of Invention:	Country:	Application No.	Filing Date:
ANTIBODIES DIRECTED TO MONOCYTE CHEMO-ATTRACTANT PROTEIN-1 (MCP-1) AND USES THEREOF	AU	2003265575	8/19/2003
ANTIBODIES DIRECTED TO MONOCYTE CHEMO-ATTRACTANT PROTEIN-1 (MCP-1) AND USES THEREOF	CA	2496419	8/19/2003
ANTIBODIES DIRECTED TO MONOCYTE CHEMO-ATTRACTANT PROTEIN-1 (MCP-1) AND USES THEREOF	EP	03788686.8	8/19/2003
ANTIBODIES DIRECTED TO MONOCYTE CHEMO-ATTRACTANT PROTEIN-1 (MCP-1) AND USES THEREOF	HK	05110530.1	8/19/2003
ANTIBODIES DIRECTED TO MONOCYTE CHEMO-ATTRACTANT PROTEIN-1 (MCP-1) AND USES THEREOF	JP	2004-529174	8/19/2003
ANTIBODIES DIRECTED TO MONOCYTE CHEMO-ATTRACTANT PROTEIN-1 (MCP-1) AND USES THEREOF	WO	PCT/US2003/026232	8/19/2003
ANTIBODIES DIRECTED TO ANGIOPOIETIN-2 AND USES THEREOF	AR	P050105364	12/20/2005
ANTIBODIES DIRECTED TO ANGIOPOIETIN-2 AND USES THEREOF	BD	333/2005	12/20/2005
ANTIBODIES DIRECTED TO ANGIOPOIETIN-2 AND USES THEREOF	CL	3372-2005	12/21/2005
ANTIBODIES DIRECTED TO ANGIOPOIETIN-2 AND USES THEREOF	MT	3190	12/20/2005
ANTIBODIES DIRECTED TO ANGIOPOIETIN-2 AND USES THEREOF	MY	PI20056013	12/19/2005
ANTIBODIES DIRECTED TO ANGIOPOIETIN-2 AND USES THEREOF	WO	PCT/US2005/045657	12/19/2005

PATENT
REEL: 019654 FRAME: 0975

PATENT
REEL: 037319 FRAME: 0405

PATENT
Page 4

Title of Invention:	Country:	Application No.	Filing Date:
ANTIBODIES DIRECTED TO ANGIOPOIETIN-2 AND USES THEREOF	PK	1234/2005	12/20/2005
ANTIBODIES DIRECTED TO ANGIOPOIETIN-2 AND USES THEREOF	SA	05260427	12/21/2005
ANTIBODIES DIRECTED TO ANGIOPOIETIN-2 AND USES THEREOF	TH	107272	12/20/2005
ANTIBODIES DIRECTED TO ANGIOPOIETIN-2 AND USES THEREOF	TW	094145705	12/21/2005
ANTIBODIES DIRECTED TO ANGIOPOIETIN-2 AND USES THEREOF	UY	29288	12/21/2005
ANTIBODIES DIRECTED TO ANGIOPOIETIN-2 AND USES THEREOF	VE	02665	12/21/2005
ANTIBODIES DIRECTED TO CD20 AND USES THEREOF	AR	P060102294	6/1/2006
ANTIBODIES DIRECTED TO CD20 AND USES THEREOF	CL	1347-2006	6/2/2006
ANTIBODIES DIRECTED TO CD20 AND USES THEREOF	MT	3513	5/30/2006
ANTIBODIES DIRECTED TO CD20 AND USES THEREOF	MY	PI20062516	5/31/2006
ANTIBODIES DIRECTED TO CD20 AND USES THEREOF	WO	PCT/US2006/020408	5/25/2006
ANTIBODIES DIRECTED TO CD20 AND USES THEREOF	PK	556/2006	5/30/2006
ANTIBODIES DIRECTED TO CD20 AND USES THEREOF	SA	06270159	6/3/2006
ANTIBODIES DIRECTED TO CD20 AND USES THEREOF	TH	0601002467	5/31/2006
ANTIBODIES DIRECTED TO CD20 AND USES THEREOF	TW	095119438	6/1/2006
ANTIBODIES DIRECTED TO CD20 AND USES THEREOF	UY	29573	6/1/2006
ANTIBODIES DIRECTED TO CD20 AND USES THEREOF	VE	01225-2006	6/2/2006
BINDING PROTEINS SPECIFIC FOR INSULIN-LIKE GROWTH FACTORS AND USES THEREOF	AR	P060105469	12/12/2006

PATENT
REEL: 019654 FRAME: 0976

PATENT
REEL: 037319 FRAME: 0406

PATENT
Page 5

Title of Invention:	Country:	Application No.	Filing Date:
BINDING PROTEINS SPECIFIC FOR INSULIN-LIKE GROWTH FACTORS AND USES THEREOF	CL	2006-3507	12/13/2006
BINDING PROTEINS SPECIFIC FOR INSULIN-LIKE GROWTH FACTORS AND USES THEREOF	GC	GCC/P/2006/7409	12/13/2006
BINDING PROTEINS SPECIFIC FOR INSULIN-LIKE GROWTH FACTORS AND USES THEREOF	MT	3841	12/7/2006
BINDING PROTEINS SPECIFIC FOR INSULIN-LIKE GROWTH FACTORS AND USES THEREOF	WO	PCT/US2006/047059	12/8/2006
BINDING PROTEINS SPECIFIC FOR INSULIN-LIKE GROWTH FACTORS AND USES THEREOF	PK	1605/2006	12/5/2006
BINDING PROTEINS SPECIFIC FOR INSULIN-LIKE GROWTH FACTORS AND USES THEREOF	TH	0601006183	12/12/2006
BINDING PROTEINS SPECIFIC FOR INSULIN-LIKE GROWTH FACTORS AND USES THEREOF	TW	095146733	12/13/2006
BINDING PROTEINS SPECIFIC FOR INSULIN-LIKE GROWTH FACTORS AND USES THEREOF	UY	30.002	12/11/2006
BINDING PROTEINS SPECIFIC FOR INSULIN-LIKE GROWTH FACTORS AND USES THEREOF	VE	02891-2006	12/13/2006

RECORDED: 06/29/2007

PATENT
REEL: 019654 FRAME: 0977

RECORDED: 12/17/2015

PATENT
REEL: 037319 FRAME: 0407